Feng F - Search Results

1

The Role of Leukocyte Immunoglobulin-Like Receptors Focusing on the Therapeutic Implications of the Subfamily B2.

Hu Y, Lu X, Qiu W, Liu H, Wang Q, Chen Y, Liu W, Feng F, Sun H. Hu Y, et al. Among authors: feng f. Curr Drug Targets. 2022;23(15):1430-1452. doi: 10.2174/1389450123666220822201605. Curr Drug Targets. 2022. PMID: 36017847

2

Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds.

Liu H, Qiu W, Sun T, Wang L, Du C, Hu Y, Liu W, Feng F, Chen Y, Sun H. Liu H, et al. Among authors: feng f. Acta Pharm Sin B. 2022 Apr;12(4):1781-1804. doi: 10.1016/j.apsb.2021.12.019. Epub 2021 Dec 31. Acta Pharm Sin B. 2022. PMID: 35847506 Free PMC article. Review.

3

The Development of Pharmacophore Modeling: Generation and Recent Applications in Drug Discovery.

Lu X, Yang H, Chen Y, Li Q, He SY, Jiang X, Feng F, Qu W, Sun H. Lu X, et al. Among authors: feng f. Curr Pharm Des. 2018;24(29):3424-3439. doi: 10.2174/1381612824666180810162944. Curr Pharm Des. 2018. PMID: 30101699 Review.

4

Expansion of the scaffold diversity for the development of highly selective butyrylcholinesterase (BChE) inhibitors: Discovery of new hits through the pharmacophore model generation, virtual screening and molecular dynamics simulation.

Lu X, Yang H, Li Q, Chen Y, Li Q, Zhou Y, Feng F, Liu W, Guo Q, Sun H. Lu X, et al. Among authors: feng f. Bioorg Chem. 2019 Apr;85:117-127. doi: 10.1016/j.bioorg.2018.12.023. Epub 2018 Dec 21. Bioorg Chem. 2019. PMID: 30605885

5

Discovery, molecular dynamic simulation and biological evaluation of structurally diverse cholinesterase inhibitors with new scaffold through shape-based pharmacophore virtual screening.

Yang H, Du C, Li Q, Chen T, Lu X, Li Q, Feng F, Chen Y, Liu W, Sun H. Yang H, et al. Among authors: feng f. Bioorg Chem. 2019 Nov;92:103294. doi: 10.1016/j.bioorg.2019.103294. Epub 2019 Sep 19. Bioorg Chem. 2019. PMID: 31557623

6

Small molecular Nrf2 inhibitors as chemosensitizers for cancer therapy.

Lin H, Qiao Y, Yang H, Nan Q, Qu W, Feng F, Liu W, Chen Y, Sun H. Lin H, et al. Among authors: feng f. Future Med Chem. 2020 Feb;12(3):243-267. doi: 10.4155/fmc-2019-0285. Epub 2020 Jan 17. Future Med Chem. 2020. PMID: 31950858 Review.

7

Degradation of proteins by PROTACs and other strategies.

Wang Y, Jiang X, Feng F, Liu W, Sun H. Wang Y, et al. Among authors: feng f. Acta Pharm Sin B. 2020 Feb;10(2):207-238. doi: 10.1016/j.apsb.2019.08.001. Epub 2019 Aug 13. Acta Pharm Sin B. 2020. PMID: 32082969 Free PMC article. Review.

8

Overview of AKR1C3: Inhibitor Achievements and Disease Insights.

Liu Y, He S, Chen Y, Liu Y, Feng F, Liu W, Guo Q, Zhao L, Sun H. Liu Y, et al. Among authors: feng f. J Med Chem. 2020 Oct 22;63(20):11305-11329. doi: 10.1021/acs.jmedchem.9b02138. Epub 2020 Jun 10. J Med Chem. 2020. PMID: 32463235 Review.

9

Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism.

Xing S, Li Q, Xiong B, Chen Y, Feng F, Liu W, Sun H. Xing S, et al. Among authors: feng f. Med Res Rev. 2021 Mar;41(2):858-901. doi: 10.1002/med.21745. Epub 2020 Oct 25. Med Res Rev. 2021. PMID: 33103262 Review.

10

STING, a promising target for small molecular immune modulator: A review.

Liu Y, Lu X, Qin N, Qiao Y, Xing S, Liu W, Feng F, Liu Z, Sun H. Liu Y, et al. Among authors: feng f. Eur J Med Chem. 2021 Feb 5;211:113113. doi: 10.1016/j.ejmech.2020.113113. Epub 2020 Dec 18. Eur J Med Chem. 2021. PMID: 33360799 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,599 results

Search Page